Clinical trials: Graft -Versus-host-disease
Chronic Kidney Disease(CKD), Anemia, Kidney Disease, Chronic
Impact of Dapagliflozin in Anemic Chronic Kidney Disease Patients
Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor, primarily used in the management of type 2 diabetes mellitus.
- Trial name
- NCT06897605
- Testing
- Dapagliflozin (DAPA), Erythropoiesis Stimulating Agent
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Mansoura University
Graft Versus Host Disease
Bortezomib in Patients With Chronic Graft Versus Host Disease
This study will investigate whether bortezomib can control the immune system and can be used to treat GVHD. Bortezomib has been used with not too many serious side effects in patients with multiple myeloma who will undergo…
- Trial name
- NCT01672229
- Testing
- Bortezomib
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Mehrdad Abedi, MD
Graft vs Host Disease, Kidney Transplantation
Study Evaluating Sirolimus (Rapamune™) in Solid Organ Transplant Recipients
To evaluate the safety of long-term administration of sirolimus oral solution for up to 5 additional years, or until the tablet formulation is commercially available (whichever occurs first) in solid organ transplant recipients…
- Trial name
- NCT00037531
- Testing
- Sirolimus (RAPAMUNE)
- Where
- 20 sites in United States, Canada
- Volunteers
- 769 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Leukemia, Myeloma
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
The goal of this clinical research study is to learn if giving genetically changed immune cells, called T-cells, after chemotherapy will improve the response to a stem cell transplant.
- Conditions
- Leukemia, Myeloma, Myeloproliferative Diseases
- Trial name
- NCT01875237
- Testing
- Fludarabine, Melphalan, Alemtuzumab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Bronchiolitis Obliterans, Graft Vs Host Disease
The Safety and Tolerability of Pirfenidone for BOS After HCT
This is a phase 1, non-randomized, single-arm, open label, single center clinical trial to determine the tolerability and safety of pirfenidone in patients with BOS associated with lung GVHD after hematopoietic cell transplant.
- Trial name
- STOP-BOS (NCT03315741)
- Testing
- Pirfenidone 267 MG [Esbriet]
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stanford University
GVHD, Meibomian Gland Dysfunction (Disorder)
Autologous Serum Obtained by a Closed-Circuit Collection Device
Autologous serum eye drops (ASED) are an established therapy for ocular surface diseases; however, their preparation can be costly and may not be available due to the need for germ-free conditions.
- Conditions
- GVHD, Meibomian Gland Dysfunction (Disorder), Stevens-Johnson Syndrome, Limbal Keratoconjunctivitis
- Trial name
- NCT07014059
- Testing
- Autologous Serum 20%
- Where
- Brazil
- Volunteers
- 16 people
- Sponsor
- GIANCARLO FATOBENE
Hematologic Diseases, Hematologic Malignancies
Dose-ranging Study of a Single Administration of T-cell Add-back Depleted of Host Alloreactive Cells in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor
The purpose of this study is to determine the maximum tolerated dose and evaluate the safety of the administration of donor lymphocytes depleted of alloreactive T-cells following a stem cell transplant from a related…
- Trial name
- NCT00993486
- Testing
- Donor lymphocyte preparation depleted of functional host alloreactive T-cells (ATIR)
- Where
- Canada
- Volunteers
- 19 people
- Sponsor
- Kiadis Pharma
GVHD, Acute
Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease After Allo-HSCT
A randomized (1:1) phase II open label study of DSC compared to Investigator choice Best Available Therapy (BAT) in allogeneic hematopoietic stem cell transplant recipients with Grades II-IV steroid refractory acute graft vs.
- Trial name
- 2017-00355 (NCT04118556)
- Testing
- Decidua Stroma Cells (DSC), Best available Treatment (BAT)
- Where
- 4 sites in Denmark, Norway and 1 more
- Volunteers
- 12 people
- Sponsor
- Mats Remberger
Kidney Diseases, Chronic Kidney Diseases
NAVIGATE Kidney: A Multi-level Intervention to Reduce Kidney Health Disparities
The overarching goal of this project is to refine and adapt previous work on the NAVIGATE-Kidney project for individuals with CKD.
- Trial name
- NAV-Kidney (NCT06810622)
- Testing
- Community health worker intervention, Standard Care (in control arm)
- Where
- 2 sites in United States
- Volunteers
- 448 people
- Sponsor
- University of Colorado, Denver
Allogeneic Hematopoietic Cell Transplant, Graft Versus Host Disease
Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin as Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation
This is a multi-center randomized study to compare the reduced-dose of post-transplantation cyclophosphamide (PTCY) at 35mg.kg to standard dose at 50mg/kg combined with tacrolimus and post-engraftment low dose anti-thymoglobin…
- Trial name
- NCT06705062
- Testing
- reduced-dose PTCy, Standard dose PTCY
- Where
- China
- Volunteers
- 316 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Graft vs Host Disease, Complications of Organ Transplant Stem Cells
CEC Count Changes to Support GvHD Diagnosis.
In consideration of the fact that the vascular endothelium has been shown to be a target of GvHD in early stage and that the count of CEC may represent a marker of endothelial damage, we want to evaluate the changes in CEC counts…
- Conditions
- Graft vs Host Disease, Complications of Organ Transplant Stem Cells, Endothelial Dysfunction
- Trial name
- ALLOCEC (NCT02064972)
- Testing
- Patients undergoing allo-HSCT, who manifest GvHD.
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Gastro-Intestinal Acute Graft Versus Host Disease (GI-aGVHD)
Fecal Microbiota Transplantation For The Treatment Of Gastro-Intestinal Acute GVHD
Gastro-Intestinal Acute Graft Versus Host Disease (GI-aGVHD) is a complication of allogeneic stem cell transplant which is usually treated with steroids.
- Trial name
- NCT04059757
- Testing
- Fecal Microbiota Transplantation (FMT)
- Where
- United States
- Sponsor
- Leland Metheny
Low Back Pain, Mechanical, Biofeedback, Pain, Chronic
The Effectiveness of Two Different Feedbacks in Core Stabilization Education for Chronic Nonspecific Low Back Pain
Abstract. Insufficient motor control mechanism of transversus abdominus and multifidus muscles is the most important cause of the chronic nonspecific low back pain (CNLBP).
- Trial name
- NCT03099941
- Testing
- Biofeedback
- Volunteers
- 38 people
- Sponsor
- Istanbul University
Malignant Pain, Non-malignant Pain
To Demonstrate Equivalence in Analgesic Efficacy & Bowel Function Between OXN PR Higher Dose & Lower Dose Tablet Strengths in Subjects With Non-cancer or Cancer Pain
This study is aimed to demonstrate equivalence between combinations of lower strength OXN PR tablets (OXN PR LST) and single higher strength OXN PR tablets (OXN PR HST) taken at the same overall daily dose.
- Trial name
- NCT02321397
- Testing
- Oxycodone, Naloxone
- Where
- Germany
- Volunteers
- 155 people
- Sponsor
- Mundipharma Research GmbH & Co KG
Back Pain, Low
Effects of Mackenzie and Tailored Mat Exercises in Post-Menopausal Women With Low Back Pain
Group A will receive tailored mat exercises. Group B will receive Mckenzie exercises. A baseline treatment including moist hot pack and TENS will be given to both of these groups.
- Trial name
- NCT06750380
- Testing
- Tailored mat exercise program, McKenzie exercises
- Where
- Pakistan
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Riphah International University
Chronic Graft Versus Host Disease
Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study
This trial collects clinical data and blood samples to predict the quality of response to specific treatments in patients with chronic graft-versus-host disease (cGVHD) who are about to start a new therapy.
- Trial name
- NCT04431479
- Testing
- Biospecimen Collection, Medical Chart Review, Quality-of-Life Assessment
- Where
- 10 sites in United States, Canada
- Volunteers
- 211 people
- Sponsor
- Fred Hutchinson Cancer Center
Lymphoma
Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)
The goal of this clinical research study is to study the safety of ADCETRISTM (brentuximab vedotin) in patients with Hodgkin lymphoma or ALCL who have had an allogeneic or haploidentical stem cell transplant.
- Trial name
- NCT02169505
- Testing
- Brentuximab Vedotin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Steroid Refractory GVHD
Evaluation of EFficacy and SaFEty of Leukotac (Inolimomab) in Pediatric Patients With SR-aGvHD
A Phase 3, Multicenter, open label, study to Evaluate the EFficacy and SaFEty of Leukotac® (inolimomab) in pediatric patients with steroid resistant acute Graft versus Host Disease (SR-aGvHD)
- Trial name
- EiFFEL (NCT04289103)
- Testing
- Inolimomab (Leukotac)
- Volunteers
- 65 people
- Sponsor
- ElsaLys Biotech
Graft-versus-host Disease (GVHD)
An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
To provide ruxolitinib through an expanded access program for the treatment of graft-versus-host disease (GVHD) in United States to patients who are ineligible or unable to participate in any actively enrolling Incyte-sponsored…
- Trial name
- NCT03147742
- Testing
- Ruxolitinib
- Where
- 33 sites in United States
- Sponsor
- Incyte Corporation
Chronic Graft Versus Host Disease
Tissue Immune Landscape of Graft Versus Host Disease After Allogeneic Stem Cell Transplantation (TIL-GVHD)
Graft versus Host Disease (GVHD) is frequent after allogeneic stem cell transplantation (alloSCT). GVHD occurs following 2 patterns : acute GVHD (aGVHD) or chronic GVHD (cGVHD).
- Trial name
- TIL-GVHD (NCT06247150)
- Testing
- Additional blood sample, cGVHD target tissue biopsy
- Where
- France
- Volunteers
- 70 people
- Sponsor
- University Hospital, Bordeaux
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.